New trial
Phase II Investigational HDR Brachytherapy (dose-adjusted internal radiotherapy) in cervical cancer.
- Trial ID
- NCT07022470 on ClinicalTrials.gov
- Cancer type
- Cervical Cancer
- Stage of research
- Exploratory
- Published in
- New in Oncology - July 3, 2025
This prospective non-randomized trial from Stanford University in Palo Alto evaluates a 3-fraction versus standard 4-fraction HDR brachytherapy regimen in locally advanced cervical cancer. Patients meeting dosimetric criteria receive the investigational treatment, aiming to personalize therapy and improve treatment efficiency.
More in cervical and other gynecologic cancers
-
Trial result · Sep 24, 2026
Pembrolizumab (PD-1) + Chemotherapy Sustains 5-Year OS Benefit in 1L Advanced Cervical Cancer -
New trial · Aug 13, 2026 · NCT07672782
Phase 2 tisotumab vedotin (tissue factor–targeted) MMAE ADC in recurrent/metastatic vulvar SCC. -
Trial result · Jul 16, 2026 · NCT03750539
Hypofractionated pelvic RT (37.5Gy/15fx) + weekly cisplatin shows similar pCR vs standard 50Gy/25fx in LACC surgery cohort -
Trial result · Jul 16, 2026 · NCT06265727
CRB-701 (SYS6002) Nectin-4–targeted MMAE ADC shows early ~38% unconfirmed ORR in R/M cervical cancer -
Trial result · Jul 8, 2026 · NCT06288360
Camrelizumab (PD-1) + cisplatin/nab-paclitaxel hits 100% ORR and 30% pCR in PD-L1–negative LACC